Yakobson, A.; Abu Salamah, F.; Alatawneh, I.; Cohen, A.Y.; Valdman-Grinshpoun, Y.; Malek, Y.; Gothelf, I.; Abu Jama, A.; Abu Yasin, N.; Abu Juda, M.;
et al. Impact of PD-L1 Status on the Development of Cutaneous Immune-Related Adverse Events in Non-Small-Cell Lung Cancer Patients Receiving Immunotherapy. Life 2026, 16, 636.
https://doi.org/10.3390/life16040636
AMA Style
Yakobson A, Abu Salamah F, Alatawneh I, Cohen AY, Valdman-Grinshpoun Y, Malek Y, Gothelf I, Abu Jama A, Abu Yasin N, Abu Juda M,
et al. Impact of PD-L1 Status on the Development of Cutaneous Immune-Related Adverse Events in Non-Small-Cell Lung Cancer Patients Receiving Immunotherapy. Life. 2026; 16(4):636.
https://doi.org/10.3390/life16040636
Chicago/Turabian Style
Yakobson, Alexander, Fahed Abu Salamah, Ibrahim Alatawneh, Ahron Yehonatan Cohen, Yuliya Valdman-Grinshpoun, Yotam Malek, Itamar Gothelf, Ashraf Abu Jama, Nashat Abu Yasin, Mhammad Abu Juda,
and et al. 2026. "Impact of PD-L1 Status on the Development of Cutaneous Immune-Related Adverse Events in Non-Small-Cell Lung Cancer Patients Receiving Immunotherapy" Life 16, no. 4: 636.
https://doi.org/10.3390/life16040636
APA Style
Yakobson, A., Abu Salamah, F., Alatawneh, I., Cohen, A. Y., Valdman-Grinshpoun, Y., Malek, Y., Gothelf, I., Abu Jama, A., Abu Yasin, N., Abu Juda, M., Soklakova, A., Meirovitz, A., & Shalata, W.
(2026). Impact of PD-L1 Status on the Development of Cutaneous Immune-Related Adverse Events in Non-Small-Cell Lung Cancer Patients Receiving Immunotherapy. Life, 16(4), 636.
https://doi.org/10.3390/life16040636
